A Phase 1 Study of DB-2304 in Healthy Adults
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT06625671
- Locations
- π¦πΊ
Site AUS01-0, Melbourne, Victoria, Australia
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06554795
- Locations
- πΊπΈ
Site USA08-0, Newport Beach, California, United States
πΊπΈSite USA06-0, Washington, D.C., District of Columbia, United States
πΊπΈSite USA02, Florida City, Florida, United States
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT06265428
- Locations
- π¨π³
015, Bengbu, Anhui, China
π¨π³029, Hefei, Anhui, China
π¨π³001, Beijing, Beijing, China
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
- Conditions
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 532
- Registration Number
- NCT06018337
- Locations
- πΊπΈ
Research Site 1141-0, Tucson, Arizona, United States
πΊπΈResearch Site 1114-0, Fullerton, California, United States
πΊπΈResearch Site 1107-0, Los Angeles, California, United States
A Study of DB-1311 in Advanced/Metastatic Solid Tumors
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT05914116
- Locations
- πΊπΈ
Research Site 111, Tucson, Arizona, United States
πΊπΈResearch Site 116, Encinitas, California, United States
πΊπΈResearch Site 124, Fresno, California, United States
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 287
- Registration Number
- NCT05785741
- Locations
- πΊπΈ
Research Site 111, Atlanta, Georgia, United States
πΊπΈUniversity of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
πΊπΈUCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
A Study of DB-1202 Monotherapy in Advanced Solid Tumors
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05785728
- Locations
- π¨π³
Fudan University Shanghai Cancer Center, Shanghai, China
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 902
- Registration Number
- NCT05438329
- Locations
- πΊπΈ
Site 104, Houston, Texas, United States
π¨π³Site 201, Changchun, Jilin, China
π¨π³Site 202, Zhengzhou, Henan, China
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 766
- Registration Number
- NCT05150691
- Locations
- πΊπΈ
Kapi'olani Medical Center for Women and Children, Honolulu, Hawaii, United States
πΊπΈWomen's Cancer Care, Covington, Louisiana, United States
πΊπΈHoly Cross Hospital, Silver Spring, Maryland, United States